Quantum BioPharma Provides Corporate Update
A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.
On June 1 2026, Quantum BioPharma disclosed that the U.S. FDA placed the Investigational New Drug (IND) application for its lead asset Lucid‑21‑302 (Lucid‑MS) on clinical hold as of May 28, 2026. The company must submit additional information before any Phase 2 trial can begin; all previously communicated timelines for FDA review, trial initiation, and interim data are formally withdrawn. Additionally, Dr. Lakshmi P. Kotra resigned as director and from all executive positions, effective that day, though he will remain a senior clinical advisor in a non‑executive capacity. Management says the FDA’s issues are “addressable” and intends to submit a response package.
This is a material negative event. The IND clinical hold stops the Lucid‑MS program in its tracks, directly contradicting the steady stream of bullish progress reports issued over the preceding year (IND submission, safety‑study completions, new PI appointment, CRO engagement, and a promising MGH imaging study). The abrupt withdrawal of all timelines introduces significant uncertainty, and the departure of a director who was intimately involved in the MS program (Dr. Kotra had been quoted as a key opinion leader) raises questions about the robustness of the IND package and internal confidence. Although the company asserts the hold can be resolved, the combination of regulatory setback and executive disruption materially increases the risk profile, undermines credibility, and will likely delay any value‑inflecting catalyst by many months, if not longer. The share price fell from $9.50 to $7.34 on the day, confirming a negative market assessment.
Quantum BioPharma (formerly FSD Pharma) is a pre‑revenue biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders. Its flagship program is Lucid‑21‑302 (Lucid‑MS), a first‑in‑class, patented new chemical entity designed to inhibit demyelination via PAD2, providing neuroprotection for multiple sclerosis. The asset has completed Phase 1 safety studies and was poised for a Phase 2 efficacy trial, pending IND clearance. The company also holds a 19.84% equity stake and a 7% royalty (stepping down to 3% after $250 M in cumulative sales) in Unbuzzd Wellness Inc., which commercialises a dietary supplement that accelerates alcohol metabolism. Additionally, it owns a cryptocurrency portfolio valued at $6.5 M as of Q1 2026.